Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Kymab Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Kymab Ltd - Product Pipeline Review - 2016', provides an overview of the Kymab Ltd's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Kymab Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Kymab Ltd - The report provides overview of Kymab Ltd including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Kymab Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Kymab Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Kymab Ltd's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Kymab Ltd - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Kymab Ltd's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Kymab Ltd Snapshot 6 Kymab Ltd Overview 6 Key Facts 6 Kymab Ltd - Research and Development Overview 7 Key Therapeutic Areas 7 Kymab Ltd - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Kymab Ltd - Pipeline Products Glance 11 Kymab Ltd - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Kymab Ltd - Drug Profiles 13 HIV vaccine - Drug Profile 13 Product Description 13 Mechanism Of Action 13 R&D Progress 13 KY-1003 - Drug Profile 15 Product Description 15 Mechanism Of Action 15 R&D Progress 15 KY-1005 - Drug Profile 16 Product Description 16 Mechanism Of Action 16 R&D Progress 16 KY-1006 - Drug Profile 17 Product Description 17 Mechanism Of Action 17 R&D Progress 17 KY-1007 - Drug Profile 18 Product Description 18 Mechanism Of Action 18 R&D Progress 18 KY-1016 - Drug Profile 19 Product Description 19 Mechanism Of Action 19 R&D Progress 19 KY-1034 - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 KY-1041 - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 KY-1043 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 KY-1044 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 KY-1047 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 KY-1050 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 KY-1051 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 KY-1055 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Vaccines for HIV and Bordetella pertussis Infections - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Kymab Ltd - Pipeline Analysis 29 Kymab Ltd - Pipeline Products by Target 29 Kymab Ltd - Pipeline Products by Molecule Type 30 Kymab Ltd - Pipeline Products by Mechanism of Action 31 Kymab Ltd - Dormant Projects 32 Kymab Ltd - Locations And Subsidiaries 33 Head Office 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Kymab Ltd, Key Facts 6 Kymab Ltd - Pipeline by Indication, 2016 8 Kymab Ltd - Pipeline by Stage of Development, 2016 9 Kymab Ltd - Monotherapy Products in Pipeline, 2016 10 Kymab Ltd - Preclinical, 2016 11 Kymab Ltd - Discovery, 2016 12 Kymab Ltd - Pipeline by Target, 2016 29 Kymab Ltd - Pipeline by Molecule Type, 2016 30 Kymab Ltd - Pipeline Products by Mechanism of Action, 2016 31 Kymab Ltd - Dormant Developmental Projects,2016 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.